Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

Rikke B. Holmgaard, Dmitriy Zamarin, David H. Munn, Jedd D. Wolchok, James P. Allison

Research output: Contribution to journalArticle

355 Scopus citations

Fingerprint Dive into the research topics of 'Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4'. Together they form a unique fingerprint.

Medicine & Life Sciences